Department of Oncology and Radiotherapy

StartResearch TeamsDepartment of Oncology and ...
Department of Haematology and TransplantologyLaboratory of Molecular Bacteriology
Department of Oncology and Radiotherapy Department of Pharmaceutical Technology
Department of Biopharmacy and PharmacodynamicsClinical Immunology and Transplantology Unit at the Department of Immunology
Arterial Hypertension Unit at the Department of Hypertension and DiabetologyChair and Department of Physiopathology

Head: Prof. Jacek Jassem, M.D., Ph.D.

Prof. Jacek Jassem, M.D., Ph.D.
Prof. Jacek Jassem, M.D., Ph.D.


Field of scientific activity:
The clinical activity of the department includes treatment of malignant diseases using anticancer agents and radiation. There is also a modern research unit focusing on clinical trials and translation research combining cancer molecular features with clinical behaviour.

Main achievements:
The team has developed and validated a few novel tumour biomarkers (prognostic signatures based on molecular techniques) in lung cancer and breast cancer. Long-term collaboration with University of Colorado resulted in numerous publications in the field of predictive assays for the benefit from targeted therapies in lung cancer.

Scientific and service offer:
The department has its own Clinical Research Unit. The offer includes a wide range of investigations on new anticancer substances and radiotherapy techniques. The unit focuses on the development and validation of prognostic and predictive molecular assays with a real possibility of their implementation into the clinics.

International Projects:

2004: Translating molecular knowledge into early breast cancer management building on the BIG (Breast International Group) network for improved treatment tailoring – 6 FP – TRANSBIG

2006: Trans European Network for Clinical Trial Service – e-TEN – TENALEA

2009: Developing vocational skills in oncology through e-learning – Leonardo da Vinci – ONCOVIDEOS

2012: European Thoracic Oncology Platform – ETOP: LUNGSCAPE.

Commercialization and technology transfer:

I. Patent BP/72/09: ”Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage I-IIIA” (issued by the Patent Office of the Republic of Poland on 18 June 2012; international, US and EU patent pending)

II. Patent: “New markers and the method of determination of the risk of distant metastases in patients with non-small cell lung cancer in stage I-IIIA“ application at the Patent Office of the Republic of Poland (P. 394921) and USA Patent Office (serial no. US 13/474708.)

III. Patent #2011/0262,453 “Markers of assessing the susceptibility of cancer to IGF-1R treatment”

Contact details:
Department of Oncology and Radiotherapy
Prof. Jacek Jassem, M.D., Ph.D.
jjassem@gumed.edu.pl
+ 48 58 349 22 41